A BILL FOR AN ACT

RELATING TO HEALTH.

BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF HAWAII:

1 SECTION 1. The legislature finds that prescription refills 2 play an important role in allowing patients to get their 3 medication without frequent office visits. Refills also support 4 patient adherence to chronic medications. Typical 5 pharmacotherapy requires a patient's adherence to the regimen to 6 achieve the therapeutic outcome, especially in patients with 7 chronic conditions. Abrupt cessation or unplanned interruption 8 of therapy may lead to undesirable outcomes. It is paramount 9 for the pharmacist to ensure the patient's regimen is not 10 disrupted and medications are dispensed in a timely manner. 11 The legislature further finds that during times of natural 12 disasters or public health emergencies, there may be significant 13 challenges that impede a patient's ability to timely receive a 14 necessary prescription. For example, the COVID-19 pandemic

16 quarantine mandates forced patients to cancel existing

forced some providers to limit office hours. Additionally,

2024-0204 HB HMSO-3

15

H.B. NO. 1836

1 appointments. These challenges resulted in gap periods without 2 medications.

3 The purpose of this Act is to provide clear guidance for pharmacists to act in the best interest of the patients by 4 5 minimizing gap periods without medications during a state of 6 emergency by allowing pharmacists to refill prescriptions of up 7 to thirty-day supplies of dangerous drugs and dangerous devices 8 if the prescriber is unavailable to authorize the refill and if, 9 in the pharmacist's professional judgment, failure to refill the 10 prescription may interrupt the patient's ongoing care and have a 11 significant adverse effect on the patient's well-being.

SECTION 2. Chapter 461, Hawaii Revised Statutes, is amended by adding a new section to be appropriately designated and to read as follows:

15 "§461- Refills without prescriber's authorization

16 during state of emergency. (a) During a state of emergency

17 declared pursuant to section 127A-14, a prescription of up to a

18 thirty-day supply of a dangerous drug or dangerous device may be

19 refilled without the practitioner's authorization if the

20 practitioner is unavailable to authorize the refill and if, in

21 the pharmacist's professional judgment, failure to refill the



Page 3

H.B. NO. 1830

1	prescription may interrupt the patient's ongoing care and have a
2	significant adverse effect on the patient's well-being.
3	(b) Prior to refilling a prescription pursuant to this
4	section, the pharmacist shall make every reasonable effort to
5	contact the practitioner. The pharmacist shall make an
6	appropriate record, including the basis for proceeding under
7	this section.
8	(c) The pharmacist shall inform the patient that the
9	prescription was refilled pursuant to this section.
10	(d) The pharmacist shall make every reasonable effort to
11	contact the practitioner within a reasonable period of time of
12	any refills dispensed pursuant to this section.
13	(e) The practitioner shall not incur any liability as the
14	result of a refilling of a prescription pursuant to this
15	section.
16	(f) Notwithstanding any law to the contrary, a person may
17	possess a dangerous drug or dangerous device dispensed pursuant
18	to this section.
19	(g) For purposes of this section, "dangerous drug or
20	dangerous device" means any drug or device unsafe for self-use
21	in human beings or animals. "Dangerous drug or dangerous



H.B. NO. 1836

1	device" includes any drug or device that by federal or state law
2	may be lawfully dispensed only on a practitioner's order.
3	"Dangerous drug or dangerous device" does not include a
4	controlled substance, as defined in section 329-1."
5	SECTION 3. Section 328-16, Hawaii Revised Statutes, is
6	amended as follows:
7	1. By amending subsections (a) and (b) to read:
8	"(a) A prescription drug shall be dispensed only if its
9	label bears the following:
10	(1) The name, business address, and telephone number of
11	the seller. The business address shall be the
12	physical location of the pharmacy or the dispensing
13	<pre>practitioner's office;</pre>
14	(2) Except as otherwise authorized for expedited partner
15	therapy in section 453-52 or an opioid antagonist in
16	section 461-11.8, the name of the person for whom the
17	drug was prescribed or the name of the owner of the
18	animal for which the drug was prescribed;
19	(3) The serial number of the prescription;
20	(4) The date the prescription was prepared;

2024-0204 HB HMSO-3

Page 4

,

H.B. NO. 1636

1	(5)	The name of the practitioner if the seller is not the			
2		practitioner;			
3	(6)	The name, strength, and quantity of the drug;			
4	(7)	The "use by" date for the drug, which shall be:			
5		(A) The expiration date on the manufacturer's			
6		container; or			
7		(B) One year from the date the drug is dispensed,			
8		whichever is earlier;			
9	(8)	The number of refills available, if any;			
10	(9)	In the case of the dispensing of an equivalent generic			
11		drug product, the statement "same as (brand name of			
12		the drug product prescribed or the referenced listed			
13		drug name)", or words of similar meaning;			
14	(10)	In the case of the dispensing of an interchangeable			
15		biological product, the statement "interchangeable			
16		with (brand name of the biological product prescribed			
17		or the referenced biological drug name)", or words of			
18		similar meaning; and			
19	(11)	Specific directions for the drug's use; provided that			
20		if the specific directions for use are too lengthy for			
21		inclusion on the label, the notation "take according			

2024-0204 HB HMSO-3

H.B. NO. **\836**

to written instructions" may be used if separate
written instructions for use are actually issued with
the drug by the practitioner or the pharmacist, but in
no event shall the notation "take as directed",
referring to oral instructions, be considered
acceptable.

7 If any prescription for a drug does not indicate the number of times it may be refilled, if any, the pharmacist shall not 8 9 refill that prescription unless subsequently authorized to do so 10 by the practitioner $[\div]$ or pursuant to section 461- . The act 11 of dispensing a prescription drug other than a professional 12 sample or medical oxygen contrary to this subsection shall be 13 deemed to be an act that results in a drug being misbranded 14 while held for sale.

(b) In addition to the requirements enumerated in
subsection (a), a prescription drug shall be dispensed only:
(1) By a pharmacist pursuant to a valid prescription or
section 453-52, 461-1, [or] 461-11.8[;, or 461-;
(2) By a medical oxygen distributor pursuant to a
prescription or certificate of medical necessity;

2024-0204 HB HMSO-3

H.B. NO. 1836

1		provided that the drug to be dispensed is medical		
2		oxygen; or		
3	(3)	By a prac	titioner to an ultimate user; provided that:	
4		(A) Exce	pt as otherwise authorized for expedited	
5		part	ner therapy in section 453-52, the	
6		prac	titioner shall inform the patient, prior to	
7		disp	ensing any drug other than a professional	
8		samp	le, that the patient may have a written,	
9		oral	ly ordered, or electronically transmitted or	
10		conv	eyed prescription directed to a pharmacy or a	
11		medi	cal oxygen distributor of the patient's own	
12		choi	ce;	
13		(B) The	practitioner shall promptly record in the	
14		prac	titioner's records:	
15		(i)	The prescription in full;	
16		(ii)	The name, strength, and quantity of the	
17			drug, and specific directions for the drug's	
18			use;	
19		(iii)	The date the drug was dispensed;	
20		(iv)	Except as otherwise authorized for expedited	
21			partner therapy in section 453-52 or for an	



H.B. NO. 1836

1			opioid antagonist in section 461-11.8, the
2			name and address of the person for whom the
3			drug was prescribed or the name of the owner
4		·	of the animal for which the drug was
5			prescribed; and
6		(v)	Prescription drugs dispensed or prescribed
7			for expedited partner therapy as authorized
8			under section 453-52 or for an opioid
9			antagonist in section 461-11.8;
10	(C)	The	records described in subparagraph (B) shall
11		be s	ubject to the inspection of the department or
12		its	agents at all times; and
13	(D)	No u	ndisclosed rebate, refund, commission,
14		pref	erence, discount, or other consideration,
15		whet	her in the form of money or otherwise, has
16		been	offered to the practitioner as compensation
17		or i	nducement to dispense or prescribe any
18		spec	ific drug in preference to other drugs that
19		migh	t be used for the identical therapeutic
20		indi	cation."
21	2. By am	endin	g subsection (d) to read:



H.B. NO. 1836

1	"(d) Any prescription may be refilled by the pharmacy and
2	a prescription for medical oxygen may be refilled by the medical
3	oxygen distributor if that refilling is authorized by the
4	practitioner either:
5	(1) In the original prescription; or
6	(2) By oral or electronic order, which shall be promptly
7	recorded and filed by the receiving pharmacist or
8	medical oxygen distributor[-].
9	or the refilling is conducted pursuant to section 461"
10	SECTION 4. Statutory material to be repealed is bracketed
11	and stricken. New statutory material is underscored.
12	SECTION 5. This Act shall take effect upon its approval.
13	
	INTRODUCED BY:

JAN 1 8 2024



H.B. NO. 1836

Report Title:

Pharmacists; Refills; Dangerous Drugs; Dangerous Devices; State of Emergency

Description:

Allows pharmacists, during declared states of emergency, to refill prescriptions of up to thirty-day supplies of dangerous drugs and dangerous devices if the prescriber is unavailable or cannot be contacted to authorize the refill and if, in the pharmacist's professional judgment, failure to refill the prescription might interrupt the patient's ongoing care and have a significant adverse effect on the patient's well-being.

The summary description of legislation appearing on this page is for informational purposes only and is not legislation or evidence of legislative intent.

